89 related articles for article (PubMed ID: 18509635)
1. Tetrafluorophenolate of HBED-CC: a versatile conjugation agent for 68Ga-labeled small recombinant antibodies.
Eder M; Wängler B; Knackmuss S; LeGall F; Little M; Haberkorn U; Mier W; Eisenhut M
Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1878-86. PubMed ID: 18509635
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and Evaluation of Radiogallium Labeled Bone-Imaging Probes Using Oligo-γ-Carboxy Glutamic Acid Peptides as Carriers to Bone.
Ogawa K; Nishizawa K; Mishiro K; Effendi N; Fuchigami T; Munekane M; Wakabayashi H; Kinuya S
Mol Pharm; 2024 May; 21(5):2375-2382. PubMed ID: 38573777
[TBL] [Abstract][Full Text] [Related]
3. Theranostic Agent Targeting Bone Metastasis: A Novel [
Jin W; Zhao R; Wang R; Choi SR; Ploessl K; Alexoff D; Wu Z; Zhu L; Kung HF
J Med Chem; 2024 Mar; 67(6):4793-4803. PubMed ID: 38450559
[TBL] [Abstract][Full Text] [Related]
4. Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer.
Eder M; Neels O; Müller M; Bauder-Wüst U; Remde Y; Schäfer M; Hennrich U; Eisenhut M; Afshar-Oromieh A; Haberkorn U; Kopka K
Pharmaceuticals (Basel); 2014 Jun; 7(7):779-96. PubMed ID: 24983957
[TBL] [Abstract][Full Text] [Related]
5. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging.
Eder M; Schäfer M; Bauder-Wüst U; Hull WE; Wängler C; Mier W; Haberkorn U; Eisenhut M
Bioconjug Chem; 2012 Apr; 23(4):688-97. PubMed ID: 22369515
[TBL] [Abstract][Full Text] [Related]
6. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer.
Afshar-Oromieh A; Zechmann CM; Malcher A; Eder M; Eisenhut M; Linhart HG; Holland-Letz T; Hadaschik BA; Giesel FL; Debus J; Haberkorn U
Eur J Nucl Med Mol Imaging; 2014 Jan; 41(1):11-20. PubMed ID: 24072344
[TBL] [Abstract][Full Text] [Related]
7. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.
Afshar-Oromieh A; Malcher A; Eder M; Eisenhut M; Linhart HG; Hadaschik BA; Holland-Letz T; Giesel FL; Kratochwil C; Haufe S; Haberkorn U; Zechmann CM
Eur J Nucl Med Mol Imaging; 2013 Apr; 40(4):486-95. PubMed ID: 23179945
[TBL] [Abstract][Full Text] [Related]
8. (68)Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients.
Sterzing F; Kratochwil C; Fiedler H; Katayama S; Habl G; Kopka K; Afshar-Oromieh A; Debus J; Haberkorn U; Giesel FL
Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):34-41. PubMed ID: 26404016
[TBL] [Abstract][Full Text] [Related]
9. The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions.
Afshar-Oromieh A; Hetzheim H; Kratochwil C; Benesova M; Eder M; Neels OC; Eisenhut M; Kübler W; Holland-Letz T; Giesel FL; Mier W; Kopka K; Haberkorn U
J Nucl Med; 2015 Nov; 56(11):1697-705. PubMed ID: 26294298
[TBL] [Abstract][Full Text] [Related]
10. Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer.
Dietlein M; Kobe C; Kuhnert G; Stockter S; Fischer T; Schomäcker K; Schmidt M; Dietlein F; Zlatopolskiy BD; Krapf P; Richarz R; Neubauer S; Drzezga A; Neumaier B
Mol Imaging Biol; 2015 Aug; 17(4):575-84. PubMed ID: 26013479
[TBL] [Abstract][Full Text] [Related]
11. Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.
Szabo Z; Mena E; Rowe SP; Plyku D; Nidal R; Eisenberger MA; Antonarakis ES; Fan H; Dannals RF; Chen Y; Mease RC; Vranesic M; Bhatnagar A; Sgouros G; Cho SY; Pomper MG
Mol Imaging Biol; 2015 Aug; 17(4):565-74. PubMed ID: 25896814
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M
J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127
[TBL] [Abstract][Full Text] [Related]
13. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer.
Afshar-Oromieh A; Avtzi E; Giesel FL; Holland-Letz T; Linhart HG; Eder M; Eisenhut M; Boxler S; Hadaschik BA; Kratochwil C; Weichert W; Kopka K; Debus J; Haberkorn U
Eur J Nucl Med Mol Imaging; 2015 Feb; 42(2):197-209. PubMed ID: 25411132
[TBL] [Abstract][Full Text] [Related]
14. A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer.
Schäfer M; Bauder-Wüst U; Leotta K; Zoller F; Mier W; Haberkorn U; Eisenhut M; Eder M
EJNMMI Res; 2012 Jun; 2(1):23. PubMed ID: 22673157
[TBL] [Abstract][Full Text] [Related]
15. 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer.
Banerjee SR; Pullambhatla M; Byun Y; Nimmagadda S; Green G; Fox JJ; Horti A; Mease RC; Pomper MG
J Med Chem; 2010 Jul; 53(14):5333-41. PubMed ID: 20568777
[TBL] [Abstract][Full Text] [Related]
16. Radiochemistry for positron emission tomography.
Rong J; Haider A; Jeppesen TE; Josephson L; Liang SH
Nat Commun; 2023 Jun; 14(1):3257. PubMed ID: 37277339
[TBL] [Abstract][Full Text] [Related]
17. Peptide-based positron emission tomography probes: current strategies for synthesis and radiolabelling.
Failla M; Floresta G; Abbate V
RSC Med Chem; 2023 Apr; 14(4):592-623. PubMed ID: 37122545
[TBL] [Abstract][Full Text] [Related]
18. The diagnostic performance of
Pang W; Cheng S; Du Z; Du S
Front Oncol; 2023; 13():1145759. PubMed ID: 36959787
[TBL] [Abstract][Full Text] [Related]
19. Optimization of Precursor Preparation in PSMA-11 Radiolabeling to Obtain a Highly Reproducible Radiochemical Yield.
Iudicello A; Boschi S; Ghedini P; Lohr F; Panareo S
Pharmaceuticals (Basel); 2022 Mar; 15(3):. PubMed ID: 35337140
[TBL] [Abstract][Full Text] [Related]
20. Cold Kit Labeling: The Future of
Lepareur N
Front Med (Lausanne); 2022; 9():812050. PubMed ID: 35223907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
